Specifically, in HFpEF and CAD, studies like DELIVER and EMPEROR-Preserved have shown that SGLT2 inhibitors reduced mortality and heart failure hospitalizations and improved symptoms, leading to their strong recommendation for HFpEF in 2023 ESC guidelines. The gene discussed is SLC5A2; the disease is coronary artery disorder.